MiMedx Group Inc (MDXG) Given Consensus Rating of “Hold” by Brokerages

MiMedx Group Inc (NASDAQ:MDXG) has been given an average rating of “Hold” by the seven research firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $13.50.

A number of research firms have issued reports on MDXG. ValuEngine upgraded MiMedx Group from a “sell” rating to a “hold” rating in a report on Monday, July 2nd. BidaskClub upgraded MiMedx Group from a “strong sell” rating to a “sell” rating in a report on Thursday, June 28th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of MiMedx Group in a report on Thursday, March 15th.

Get MiMedx Group alerts:

MiMedx Group traded down $0.41, reaching $3.35, during trading hours on Monday, Marketbeat reports. 6,406,683 shares of the stock were exchanged, compared to its average volume of 3,563,550. The stock has a market cap of $417.49 million, a PE ratio of 17.91 and a beta of 1.56. MiMedx Group has a 12 month low of $3.20 and a 12 month high of $18.25.

Several hedge funds and other institutional investors have recently made changes to their positions in MDXG. Consonance Capital Management LP bought a new position in MiMedx Group during the fourth quarter worth about $75,543,000. Senzar Asset Management LLC acquired a new stake in MiMedx Group during the fourth quarter worth approximately $9,159,000. UBS Group AG lifted its position in MiMedx Group by 681.0% during the first quarter. UBS Group AG now owns 758,711 shares of the medical equipment provider’s stock worth $5,288,000 after acquiring an additional 661,559 shares during the last quarter. Think Investments LP acquired a new stake in MiMedx Group during the fourth quarter worth approximately $7,826,000. Finally, Allianz Asset Management GmbH lifted its position in MiMedx Group by 868.0% during the fourth quarter. Allianz Asset Management GmbH now owns 493,749 shares of the medical equipment provider’s stock worth $6,226,000 after acquiring an additional 442,744 shares during the last quarter. Institutional investors own 75.30% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.